NasdaqGS:GLUEBiotechs
Monte Rosa Therapeutics (GLUE) Is Down 5.0% After Cyclin E1 Degrader Data - Has The Bull Case Changed?
Monte Rosa Therapeutics recently presented preclinical data at the AACR 2026 meeting in San Diego showing its first-in-class cyclin E1-directed molecular glue degrader, MRT-55811, produced selective cyclin E1 degradation, downstream pathway suppression, and tumor regression in CCNE1-amplified models.
The work suggests a potential way to directly target a historically “undruggable” oncogene across multiple CCNE1-amplified solid tumors while sparing non-amplified cells.
We’ll now look at how...